A Study of Ramucirumab (LY3009806) in Combination With Paclitaxel in Participants With Gastric Cancer

Inclusion Criteria:

- The participant has a diagnosis of gastric or GEJ adenocarcinoma.

- The participant has disease progression during or within 4 months after last dose of
first-line chemotherapy or during or within 6 months after the last dose of
neoadjuvant or adjuvant therapy.

- The participant received combination chemotherapy, which must include a platinum
and/or a fluoropyrimidine and must not include a taxane or antiangiogenic agent.

- The disease is evaluable by imaging per Response Evaluation Criteria in Solid Tumors
1.1.

- The participant has an Eastern Cooperative Oncology Group performance status of 0 or
1.

- The participant has adequate organ function:

- Total bilirubin ≤1.5 × the upper limit of normal (ULN) and alanine
aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × ULN. If the
liver has tumor involvement, AST and ALT <5 × ULN.

- Serum creatinine ≤1.5 × ULN or calculated creatinine clearance ≥50
milliliters/minute.

- Urinary protein is <2+.

- Absolute neutrophil count ≥1.5 × 10^9/liter (L), platelets ≥100 × 10^9/L, and
hemoglobin ≥9 grams/deciliter (5.58 millimoles/L).

- International normalized ratio ≤1.5 × ULN and partial thromboplastin time ≤5
seconds above ULN.

- The participant has an estimated life expectancy of minimum 12 weeks.

- The participant has resolution to Grade 1 or less by Common Terminology Criteria for
Adverse Events Version 4.0, of all clinically significant toxic effects of previous
therapy.

- The participant, if male, is sterile or agrees to use a reliable method of birth
control.

- The participant, if female, is surgically sterile, is postmenopausal, or agrees to use
a highly effective method of birth control.

- The participant, if female and of child-bearing potential, must have a negative
pregnancy test.

Exclusion Criteria:

- The participant is receiving therapy with any of the following:

- Nonsteroidal anti-inflammatory agents.

- Other anti-platelet agents; Aspirin use at doses up to 325 milligrams (mg)/day is
permitted.

- The participant received radiotherapy within 14 days prior to randomization.

- The participant received previous chemotherapy with a cumulative dose of >900 mg per
meter squared (mg/m^2) of epirubicin or >400 mg/m^2 of doxorubicin.

- The participant has documented brain metastases or leptomeningeal disease.

- The participant has a significant bleeding disorder or vasculitis.

- The participant experienced any arterial thromboembolic event within 6 months.

- The participant has symptomatic congestive heart failure or symptomatic cardiac
arrhythmia.

- The participant has uncontrolled hypertension, despite antihypertensive intervention.

- The participant underwent major surgery within 28 days.

- The participant has a history of gastrointestinal perforation or fistula within 6
months.

- The participant has a history of inflammatory bowel disease or Crohn's disease
requiring medical intervention within 12 months.

- The participant has bowel obstruction or history of chronic diarrhea that is
considered clinically significant.

- The participant has either of the following:

- Child-pugh B or C cirrhosis.

- The participant has a serious illness or medical condition including:

- Human immunodeficiency virus infection.

- The participant has a concurrent active malignancy other than the following:

- Nonmelanomatous skin cancer.

- In situ carcinoma of the cervix or other noninvasive carcinoma or in situ
neoplasm.

- The participant has a serious nonhealing: (a) wound, (b) peptic ulcer, or (c) bone
fracture.

- The participant experienced any Grade 3 or 4 venous thromboembolic event that is not
adequately treated.